Advanced Cardiac Therapeutics Completes Successful First-in-Man

Advanced Cardiac Therapeutics, Inc., a developer and manufacturer of a proprietary and unique open-irrigated radio frequency (“RF”) ablation technology, tells us that its technology has been successfully used to treat 12 patients suffering from Atrial Fibrillation (“AFIB”) in Prague, Czech Republic.

Background

Advanced Cardiac Therapeutics, Inc. (ACT) is a pre-commercial, medical device company that designs and manufactures a catheter-based system for the treatment of patients with AFIB. ACT’s technology is the only system in the world to leverage feedback from four unique capabilities: temperature sensing, low irrigation flow rates, high resolution EGM attenuation (to differentiate tissue types) and contact sensing.

The newly reported ACT first-in-man study was designed to evaluate the safety and effectiveness of the ACT system. The patients were treated by the study’s principal investigator, Dr. Vivek Reddy, Director of Cardiac Arrhythmia Services at Mount Sinai Hospital.

The study demonstrated that the four system features work in harmony to optimally control lesion formation, reduce ablation times and reduce infused fluid volumes. For the 12 patients, the safety end points were met and 100% acute success was achieved. In addition, the average “RF-on-time” per patient was 24 minutes and 49 seconds, the average ablation application duration was 17.1 seconds and, on average, these patients received only 406 ml of irrigation fluid during the entire Pulmonary Vein Isolation procedure.

Investigator comments

According to Dr. Reddy, “What is truly extraordinary about the ACT technology is its ability to leverage temperature sensing to ablate efficiently, with ablation times that are reduced by over 50%. This technology provides a level of feedback to the operator that is greater than anything currently on the market and, accordingly, the system has the potential to change the way electrophysiologists perform RF ablation for a host of arrhythmias, including AFIB.”

Company comments

ACT’s CEO, Duke Rohlen, commented, “The ACT system that was successfully used in humans last week validated its potential to completely redefine open-irrigated RF ablation technology.” The ACT technology combines a state of the art generator with a novel temperature-sensing, low flow catheter that incorporates multiple sensors into a diamond heat shunting, high resolution tip configuration. The technology is the first in the world to combine and leverage four unique capabilities:

Source: PR Newswire

Share your thoughts

Your email address will not be published.